氟达拉滨的药代动力学及其与阿糖胞苷协同作用的研究进展  

Research progress on pharmacokinetics of fludarabine and its synergistic effect with cytarabine

作　　者：王玲[1] 陈芳源[1] 

机构地区：[1]上海交通大学医学院仁济医院血液内科,上海200001

出　　处：《上海交通大学学报（医学版）》2007年第8期1021-1024,共4页Journal of Shanghai Jiao tong University:Medical Science

摘　　要：氟达拉滨(F-ara-A)作为一种治疗白血病的药物。通过从分子生物学角度研究其作用机制和药代动力学,证明了该药除具有抗肿瘤作用外,还对阿糖胞苷(Ara-C)有增敏作用。在以F-ara-A和Ara-C为基础的临床治疗中,最常见的是FLAG方案,主要用于高危骨髓增生异常综合征及白血病患者。文章综述F-ara-A联合Ara-C在白血病治疗上的研究进展。As a drug for leukaemia, fludarabine has been widely investigated recently. Study of its pharmacokinetics and working mechanisms indicates that besides the anti-tumour effect, it has the synergistic effect with cytarabine. The FLAG regimen based on the combination of fludarabine and cytarabine is now＇commonly employed for treating the patients with high-risk myelodysplastic syndrome and leukemia. This article reviews the research progress on the regimen of fludarabine combined with cytarabine for treating the patients with leukemia.

关 键 词：氟达拉滨 药代动力学 阿糖胞苷 增敏作用 

分 类 号：R96[医药卫生—药理学]